Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss. We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.
[powerpress]
Below you'll find the audio and video versions of the podcast, along with the transcript (no real figures to go with this one).
Molecular Markers SM Pt 4 Panel Discussion Audio Podcast
Molecular Markers SM Pt 4 Panel Discussion Transcript
We'll continue with a presentation by Dr. Spigel on the value and challenges of incorporating molecular markers into the design of clinical trials in lung cancer.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…